Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Customers choose Mycronic’s new MYPro Line

Mycronic, the leading Swedish high-tech company providing production equipment with high precision and flexibility to the electronics industry, is receiving high interest from customers for the new MYPro Line, a complete SMT assembly solution designed for smart factory connectivity, comprising state-of-the-art jet printing, 3D SPI, pick-and-place, 3D AOI and intelligent storage solutions. With the MYPro line, customers can achieve more flexible and profitable electronics production.Mycronic has received two new orders on two different full-line solutions. Flexibility, high productivity and

Welcome to Saab´s Submarine Seminar

Saab is pleased to invite media, financial analysts and investors to the annual submarine seminar in Stockholm, Sweden, on August 30 2019. Join the seminar in person or online to learn more about Saab´s submarine operations.The submarine seminar 2019 will be hosted by Gunnar Wieslander, Senior Vice President and head of Saab business area Kockums. The purpose of the seminar is to increase the knowledge about Saab´s development and productions of submarines, and how we prepare for the future.   As well as an overview of the business, we intend to answer questions such as: How do you

TargetEveryone signs Fursetgruppen as new SpectrumOne customer

TargetEveryone signs the Norwegian restaurant chain Fursetgruppen as new SpectrumOne customer, starting in October. Fursetgruppen is one of Norway´s largest restaurant owners with 22 different high-end restaurant concepts, cafeterias and catering solutions. SpectrumOne will be used for reaching out to their guests with tailored messages about their restaurants, menus, seasonal offers etc. This adds a new type of industry to the SpectrumOne customer list, with a further approval of it´s relevance to a wide range of marketing demands. For further information contact: Vegard Brattum CFO

Sectra signs enterprise imaging contract with Vanderbilt Health

Linköping, Sweden and Shelton, CT – August 20, 2019 – International medical imaging IT and cybersecurity company Sectra  (STO: SECT B) will install its enterprise imaging PACS and VNA throughout Vanderbilt Health in Nashville. The Sectra solution, integrated with Epic Radiant and Cupid, will provide physicians a full patient overview on a single workstation and allow for scalability and future growth of the health system.In addition to Sectra PACS for diagnostic radiology and cardiology and the VNA to store any departmental imaging, the multi-year contract signed in

Interim report April - June 2019

Second quarter  · Net sales amounted to MSEK 2.9 (6.1) · EBITDA before extraordinary costs amounted to MSEK -6.7 (-1.7) · EBT amounted to MSEK -12.4 (-4.0) · Earnings per share before dilutions amounted to SEK -0.22 (-0.08) · MSEK 26.3 right issue completed · Accumulated cost reductions to a total of approximately 45 % Significant events after the reporting period  · Hosni Teque-Omeirat appointed as new CEO CEO statement As the new CEO of TargetEveryone I will welcome all existing and potential shareholders to a company back on the offensive. After a

Interim report January - June 2019

NET ASSET VALUE AND THE LATOUR SHARE ·The net asset value rose to SEK 127 per share, compared with SEK 100 per share at the start of the year. This is an increase of 30.3 per cent, adjusted for dividends. By comparison, the Stockholm Stock Exchange's Total Return Index (SIXRX) increased by 20.7 per cent. The net asset value was SEK 125 per share at 19 August. (1) ·The total return on the Latour share was 24.6 per cent during the year measured against the SIXRX, which rose 20.7 per cent. INDUSTRIAL OPERATIONS The second quarter ·The industrial operations' order

Nexam Chemical Holding AB (publ) Interim Report 1 January – 30 June 2019

27 percent sales growth in quarter Second quarter at a glance Operational: •          Production and sales records for Nexam Chemical as a group for both half year and quarter. •          Significant sales growth within Nexam Chemical's NEXIMID®- and NEXAMITE®-based range where            products for PET foam production are particularly strong and show the greatest increase in volume. •          Continued strong growth in the high-performance area, both in North America and Asia. •          Sales of more standardized materials in the master batch area at the same level

Eurobattery Minerals AB releases corporate presentation and implements a new communication strategy

Eurobattery Minerals AB is pleased to release an updated corporate presentation. Attached you will find information about the company, the market and its prospects. Summary corporate presentation Eurobattery Minerals is a Swedish exploration company that is focused on acquiring and developing assets in Europe with a focus on metals critical in the manufacturing of electric vehicle batteries. This includes, among other things, nickel, copper and cobalt. We strive to create a greener world by supplying the growing market for batteries and electrical vehicles with highly sort after

Aspire Global’s Half Year-Report 2019 – Strengthening Our Position

SECOND QUARTER 2019 (APR-JUNE)• Revenues increased by 32.1% to €32.8 million (24.7)• B2B revenues increased by 57.5% to €19.5 million (12.4), constituting 59.6% of total revenues.• EBITDA increased by 7.2% to €6.1 million (5.7)• EBITDA for B2B increased by 63.0% to €4.1 million (2.5), constituting 67.7% of total EBITDA• EBITDA margin amounted to 18.5% (22.8%)• EBIT amounted to €5.1 million (5.2)• Earnings after tax amounted to €4.2 million (5.3)• Earnings per share after tax amounted to €0.09 (0.11)• First time depositors (FTDs) increased by 23.6% to 99.9 thousand (80.8)

Interim report  1 January – 30 June 2019

SECOND QUARTER (APRIL – JUNE 2019) · Other operating income amounted to KSEK 1,141 (0). · Impairment of patents totalled KSEK 4,573. · Operating loss amounted to KSEK -11,307 (-8,689). · Loss for the period amounted to KSEK -11,213 (-8,669). · Cash flow from operating activities was KSEK -6,531 (-7,896). · Loss per share before dilution was SEK -0.23 (-0.42). Loss per share after dilution was SEK -0.23 (-0.42). PERIOD (JANUARY – JUNE 2019) · Other operating income amounted to KSEK 1,994 (0). · Operating loss amounted to KSEK -18,069 (-15,797). · Loss for

Nokian Tyres begins work on administration building at its US factory

Nokian Tyres, August 20, 2019 – As the company prepares to begin producing tires for commercial use in the US factory in early 2020, it aims to open its office facility in the middle part of next year.Nokian Tyres has begun construction on a world-class administration building at its new factory in Dayton, Tennessee. Complete with meeting spaces, offices, a gym, garden and other premium amenities, the facility is intended to reinforce the Scandinavian company’s life-driven culture while providing everything its employees need to be successful. “Our administration building is another

Farxiga met primary endpoint in landmark Phase III

This announcement contains inside information  20 August 2019 07:00 BST      Farxiga met primary endpoint in landmark Phase III DAPA-HF trial for the treatment of patients with heart failure      DAPA-HF is the first heart failure outcomes trial with an SGLT2 inhibitorin patients with and without type-2 diabetes  Farxiga significantly reduced the risk of cardiovascular death or worseningof heart failure when added to standard of care     AstraZeneca today announced positive results from the landmark Phase III DAPA-HF trial which showed thatFarxiga (dapagliflozin)

Bravida Denmark wins large multi-technical contract in Odense

Bravida Denmark is commissioned by the Danish Road Directorate to carry out a complete delivery of all technical installations in a new faculty building for health sciences, which will be built at the new University Hospital in Odense. The assignment has an order value of 296 mDKK.Currently, the University of Southern Denmark (SDU) has four faculties on its main campus in Odense. The new building, called SDU SUND, will be placed in direct connection with the new University Hospital in Odense. The purpose is to strengthen the collaboration between the university and the hospital, and to

Invitation to Clas Ohlson’s Q1 presentation on 4 September

Clas Ohlson will publish the interim report for the first quarter 2019/20 on 4 September at 07:00 CET. A live presentation of the report will be held at the store on Sveavägen 52 in Stockholm at 09:00 CET.Clas Ohlson invites investors, financial analysts and the media to a presentation where President and CEO Lotta Lyrå and CFO Pär Christiansen are to comment on the report. The presentation will be held at 09:00 CET in Clas Ohlson’s Lab Store at Sveavägen 52 in Stockholm. The report will be published at 07:00 CET and will be available at about.clasohlson.com/reports. For participation

Håkan Mattisson leaving his position as Clavister CFO

Örnsköldsvik, August 20, 2019. Clavister announces that Håkan Mattisson is leaving his position as group CFO per 1st of October 2019. Clavister has initiated the process to recruit a successor for the role. ”On behalf of the board and the management team, I would like to thank Håkan for his work and wish him all the best in the future,” comments John Vestberg, President and CEO of Clavister. For more information, please contact: John Vestberg, President and CEO, +46 660 299200 or ir@clavister.com The information was submitted for publication under the auspices of the above

Nordic Nanovector appoints Dr Lars Nieba as Chief Technology Officer

Oslo, Norway, 20 August 2019 Nordic Nanovector ASA (OSE: NANO) announces the appointment of Dr Lars Nieba as Chief Technology Officer and a member of the executive management team. Dr Nieba brings 20 years of leadership experience in the development of multiple pharmaceutical product candidates and innovative technologies. His role at Nordic Nanovector will be to oversee all Chemistry, Manufacturing and Controls (CMC) strategic and operational aspects of Betalutin® and all other pharmaceutical products developed by the company. Dr Nieba will join Nordic Nanovector on 1 December 2019

Itiviti and Blaze Portfolio partner to deliver superior trading connectivity and TCA services

Chicago, August 20, 2019 – Itiviti, a leading technology and service provider to financial institutions worldwide, has partnered with Blaze Portfolio, a software provider focusing on scalable investment portfolio rebalancing and real-time trade order management technology. Partnering with Itiviti enables Blaze Portfolio to offer their clients access to Itiviti’s NYFIX suite of services including, its world-class FIX connectivity network, monitoring and execution reporting.“We strive to provide our clients with the best offerings on the market,” said Bryson Pouw, CEO at Blaze Portfolio. “

Proact to offer cloud services to Scottish public sector as part of new framework

Data centre and cloud services provider Proact will now offer its industry-leading cloud and transition services to all public sector organisations in Scotland after being included in the Scottish Government’s Cloud Services framework. This multi-year Pan Government Collaborative Agreement, available for use by all public sector bodies in Scotland, became available on 3rd August 2019.Cloud Services is managed by the Scottish Procurement and Commercial Directorate, who lead and deliver public procurement at national, Central Government and Government levels, focusing on delivering savings,

Statins can prevent liver cancer

Fat-soluble statins can prevent liver cancer and reduce mortality in patients with chronic viral hepatitis. These are findings from a study conducted by researchers at Karolinska Institutet in Sweden, among others. The study is published in Annals of Internal Medicine.Chronic viral hepatitis (hepatitis B and C) are severe conditions with an increased risk of liver cancer. Currently, it is possible to treat hepatitis B and cure hepatitis C but there is no treatment that can prevent liver cancer in people whose liver has been damaged by hepatitis.   In recent years, researchers have begun

Asarina Pharma AB (publ) Interim Report Q2 2019 released

Asarina Pharma CEO Peter Nordkild: “This has been a Quarter of important milestones: last patient in for our Phase IIb PMDD study, FDA approval of our IND for Sepranolone, Clinical Trial Approval for our Phase IIa Menstrual Migraine study and growing interest from future potential partners.”FINANCIAL HIGHLIGHTS 1 April – 30 June 2019 TOTAL OPERATING COSTS SEK 28.1M (11.5M) NET RESULT -25.8M (-9.7M) CASH AND CASH EQUIVALENTS (30 JUNE 2019): SEK 109.5M (9.7M) SIGNIFICANT EVENTS DURING THE SECOND QUARTER WHO classification of PMDD In May PMDD (Premenstrual Dysphoric Disorder)

Starbreeze AB (publ) half-year Q2 2019 report

Second quarter 2019 · Net sales amounted to SEK 160.0 million (123.5). SEK 137.1 million Is attributable to the sale of the publishing rights for Psychonauts 2 and 10 Crowns. PAYDAY accounted for SEK 14.4 million (31.3). · EBITDA* amounted to SEK -25,8 million (52.4). · Depreciation, amortization and impairments totaled SEK 22.0 million (46.7). · Costs related to the reconstruction amounted to SEK 12.6 million for the quarter.  · The loss before tax amounted to SEK -60.1 million (26.2). · Basic and diluted earnings per share were SEK -0.20 (0.13). · The Stockholm

Orexo signs partnership agreement with GAIA to develop and commercialize a new digital therapy for the treatment of Opioid Use Disorder

Uppsala, Sweden – August 20, 2019. Orexo AB (publ), the fully integrated specialty pharmaceutical company addressing opioid addiction and pain, today announces it has entered into an exclusive agreement with GAIA AG (GAIA), a global leader in digital therapeutics that successfully launched its first digital health product in 2001, for a new digital therapy (DTx) for the treatment of Opioid Use Disorder (OUD). Orexo will have the exclusive global commercial rights to the product and intends to launch it in the US in 2022, subject to regulatory approval. The medically assisted treatment of

Oncopeptides appoints Klaas Bakker as new Chief Medical Officer

Stockholm - August 20, 2019 - Oncopeptides AB (Nasdaq Stockholm: ONCO) today announces that Klaas Bakker has been appointed as the new Chief Medical Officer (CMO) for Oncopeptides, starting in November.Johan Harmenberg has reached retirement age and as the company continues to expand its activities, Johan has decided to step down as CMO but continue to work as a member of the company's medical team. From 2015 to present Klaas has worked at AstraZeneca in different roles with increasing responsibility and seniority, most recently as VP Medical for their Tagrisso -TDR Franchise with global

There are no items matching the current filter
There are no more items matching the current filter
Back to top